CVS Health Q4 adjusted EPS falls to $1.19 as revenue rises 4.2%
CVS Health reported fourth-quarter and full-year 2024 results on February 12, 2025, with revenue up 4.2% in both periods but profit down sharply. The company also issued 2025 guidance of $5.75 to $6.00 in adjusted EPS and $4.58 to $4.83 in GAAP diluted EPS, which shareholders will weigh against the lower 2024 earnings.
Key points
- Q4 2024 total revenues rose to $97.7 billion, up 4.2%, while adjusted EPS fell to $1.19 from $2.12 a year earlier.
- The Health Care Benefits segment posted a Q4 adjusted operating loss of $439 million, compared with adjusted operating income of $676 million, citing higher utilization and Medicare Advantage star ratings.
- Full-year 2024 GAAP diluted EPS was $3.66 versus $6.47, and adjusted EPS was $5.42 versus $8.74.
- 2025 guidance: adjusted EPS of $5.75 to $6.00, GAAP diluted EPS of $4.58 to $4.83, and cash flow from operations of approximately $6.5 billion.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.